% | $
Quotes you view appear here for quick access.

INVO Bioscience, Inc. Message Board

  • fbg0316 fbg0316 Nov 17, 2013 9:13 AM Flag

    Thoughts On IVOB's Market Cap & Recent Development

    Just thinking about IVOB's tiny market cap of $2.49 million. This market cap coupled with the pps of $0.03 means that there are 83 million shares outstanding. This is very encouraging because there have been approximately the same amount of shares outstanding over the last several years ago, meaning the company is not diluting current shareholders to move things forward. I've been invested since 2009, and IVOB's plan all along was to get an international distribution up and running before the U.S. which they have in Latin America among a few other locales. As early as 2009, the road block in the U.S. had been funding. The FDA wanted to see more data on the procedure to consider it for U.S. use (not an approval process like drugs, but for medical devices it is a "clearance" process). IVOB would have had to either run a clinical trial, for which funding was not in place, or produce other data demonstrating safety and efficacy of the device. Now that they have both clinical trial data and a track record in Latin America they have filed a 510(k) with the FDA with 450 cycles of INVO procedures performed in order to demonstrate safety and efficacy. The potential market for IVOB's low cost alternative treatment to traditional IVF is in the hundreds of millions of dollars. FDA clearance would give the procedure a final stamp of validity to put its awareness on par with traditional IVF. The stock traded as high as $0.46 in 2009/2010. Given the current shares outstanding, a pps of $0.50 would value the company around $40 million, still very reasonable given the company's prospects. Over the last two years, the company has worked diligently to move things forward, but has done so efficiently to conserve resources (hence not a lot of marketing hype). I commend management, as they have kept their focus on their end goal of FDA approval but have not diluted shareholders to get there. This year could be a very interesting year for the company and its shareholders IMO.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.360.00(-1.37%)Apr 29 3:56 PMEDT